Outlook Therapeutics (NASDAQ:OTLK) Announces Earnings Results, Misses Estimates By $0.04 EPS

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.04), Zacks reports.

Outlook Therapeutics Stock Down 8.6 %

NASDAQ OTLK traded down $0.16 during trading hours on Tuesday, reaching $1.71. 697,307 shares of the company were exchanged, compared to its average volume of 872,649. The stock has a market capitalization of $54.69 million, a P/E ratio of -0.19 and a beta of 0.58. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85. The business's 50 day simple moving average is $1.88 and its 200-day simple moving average is $4.41.

Analysts Set New Price Targets

Several brokerages have issued reports on OTLK. BTIG Research cut their price target on Outlook Therapeutics from $50.00 to $9.00 and set a "buy" rating on the stock in a report on Friday, November 29th. Guggenheim reissued a "buy" rating and issued a $12.00 price target on shares of Outlook Therapeutics in a research report on Friday, January 17th. HC Wainwright lowered their price objective on shares of Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating on the stock in a report on Tuesday. Finally, Chardan Capital reissued a "neutral" rating and set a $3.00 target price on shares of Outlook Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $12.00.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.